PERINDOPRIL ERBUMINE

Post-LOE

Hikma

ANDAORALTABLET

Approved

Nov 2009

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

PERINDOPRIL ERBUMINE by Hikma is pro-drug for perindoprilat, which inhibits ace in human subjects and animals. Approved for nonfatal myocardial infarction. First approved in 2009.

Drug data last refreshed Yesterday

$0.0BPart D

Mechanism of Action

pro-drug for perindoprilat, which inhibits ACE in human subjects and animals. The mechanism through which perindoprilat lowers blood pressure is believed to be primarily inhibition of ACE activity. ACE is a peptidyl dipeptidase that catalyzes conversion of the inactive decapeptide, angiotensin I,…

Indications (1)

nonfatal myocardial infarction

Worked on PERINDOPRIL ERBUMINE at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.